CORT Stock Analysis: Buy, Sell, or Hold?
CORT - Corcept Therapeutics Inc.
$81.01
1.30 (1.62%)
▲
5d:
-2.54%
30d:
+35.71%
90d:
+140.87%
HOLD
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Smart Money Accumulation
None View Scanner →
Strength: 4.6/10
Get Alerted When CORT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CORT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CORT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$121.47
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$75.42
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CORT is currently trading at $81.00, which is considered extended relative to its 30-day fair value range of $62.24 to $80.81. From a valuation perspective, the stock is trading at a discount (Forward PE: 31.9) compared to its historical average (41.8). Remarkably, the market is currently pricing in an annual earnings decline of 8.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CORT is in a strong uptrend. Immediate support is located at $72.62, while resistance sits at $85.40.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $88.00 (+10.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CORT is in a strong uptrend. Immediate support is located at $72.62, while resistance sits at $85.40.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $88.00 (+10.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$62.24 -
$80.81
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.5%
Protect Your Profits
CORT is technically overbought (RSI 73). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($88.00)
Trading Range Analysis
30-Day Trading Range
$62.24 -
$80.81
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$5.33
(6.6%)
Support & Resistance Levels
Support Level
$72.62
Resistance Level
$85.40
Current Trend
Strong Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.95
Wall Street Target
$88.00
(+10.4%)
Revenue Growth (YoY)
4.9%
Earnings Growth (YoY)
-21.6%
Profit Margin
6.2%
Valuation Discount vs History
-8.6% cheaper
PE vs Historical
32.0 vs 41.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.6%
(market-implied from PE analysis)
1-Year Target
$72.85
(-9%)
2-Year Target
$66.59
(-17%)
3-Year Target
$60.86
(-24%)
3-Yr Target (if PE normalizes)
(PE: 32→42)
$79.63
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 31.9, Growth: 411.8%)
$269.02
(+238%)
Base:
(SPY PE: 21.8, Growth: 411.8%)
$183.40
(+130%)
Bear:
(PE: 18.5, Growth: 411.8%)
$155.89
(+96%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (98x PE), but valuation improves significantly next year (32x PE) as earnings recover.
Forward PE: 98.04 | Forward EPS (Implied): $0.81
Bull Case
$96.25
(+21%)
Analyst growth 15.0%, PE expands to 102.9
Base Case
$79.71
(0%)
Market implied 0.0%, PE stable at 98.0
Bear Case
$60.98
(-24%)
Severe decline -15.0%, PE contracts to 88.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 31.9 to 41.8
Stabilization Target:
$104.29
(+30.8%)
PE Expansion Potential:
+30.8%
Share & Embed Analysis
Last updated: June 23, 2026 12:58 PM ET
Data refreshes hourly during market hours. Next update: 1:58 PM
Data refreshes hourly during market hours. Next update: 1:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CORT showing a specific setup today?
Insider Activity (6 Months)
1
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
William Guyer
SELL
20000 shares
2026-04-07
Joseph K Belanoff
SELL
26198 shares
2026-03-25
William Guyer
SELL
11767 shares
2026-03-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 64 BUY |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 59 HOLD |
Advanced CORT Option Strategies
Professional options setups generated by AI based on today's CORT price and gamma walls.
